A dual inhibitor of BRD4 and HDAC1
货号:ajcx23984
CAS:2614417-90-0
分子式:C32H28ClN7O2S
分子量：610.1
溶解度:DMF: 20 mg/ml,DMSO: 10 mg/ml
纯度：98%
存储：Store at -20°C
库存：现货

Background:

TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC₅₀s = 0.074 and 0.29 µM, respectively).¹It is selective for BD2 over BD1 in BRD4 (IC₅₀= 0.72 µM) and for HDAC1 over HDAC2 (IC₅₀= 2.5 µM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G₁phase in HPAC pancreatic cancer cells when used at a concentration of 2 µM. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells.

1.Zhang, X., Zegar, T., Weiser, T., et al.Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinomaInt. J. Cancer147(10)2847-2861(2020)